Latest & greatest articles for measles

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on measles or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on measles and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for measles

61. Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study.

Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. BACKGROUND: In 2002, the UN General Assembly Special Session on Children adopted a goal to reduce deaths owing to measles by half by the end of 2005, compared with 1999 estimates. We describe efforts and progress made towards this goal. METHODS: We assessed trends in immunisation against measles on the basis of national implementation of the WHO/UNICEF comprehensive strategy for measles mortality (...) reduction, and the provision of a second opportunity for measles immunisation. We used a natural history model to evaluate trends in mortality due to measles. RESULTS: Between 1999 and 2005, according to our model mortality owing to measles was reduced by 60%, from an estimated 873,000 deaths (uncertainty bounds 634,000-1,140,000) in 1999 to 345,000 deaths (247,000-458,000) in 2005. The largest percentage reduction in estimated measles mortality during this period was in the western Pacific region (81

Lancet2007

62. Susceptibility to measles, mumps, and rubella in newly arrived adult immigrants and refugees.

Susceptibility to measles, mumps, and rubella in newly arrived adult immigrants and refugees. BACKGROUND: Despite effective vaccination programs for measles, mumps, and rubella in the United States and Canada, outbreaks continue to occur in susceptible subgroups, such as foreign-born persons. OBJECTIVE: To determine the susceptibility of newly arrived immigrants and refugees to measles, mumps, and rubella. DESIGN: Seroprevalence study. SETTING: Two hospitals and three community clinics (...) in Montreal, Quebec, Canada. PATIENTS: 1480 adult immigrants and refugees who were recruited from October 2002 to December 2004. MEASUREMENTS: Sociodemographic and clinical data and serology for measles, mumps, and rubella. RESULTS: Thirty-six percent (range, 22% to 54%) of the study population was nonimmune to at least 1 of the 3 diseases. This proportion varied by age, sex, and region of origin. In multivariate analysis and after adjustment for region of origin, age, and socioeconomic factors, immigrant

Annals of Internal Medicine2007

63. Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States.

Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States. BACKGROUND: Measles was declared eliminated from the United States in 2000 but remains endemic worldwide. In 2005, a 17-year-old unvaccinated girl who was incubating measles returned from Romania, creating the largest documented outbreak of measles in the United States since 1996. METHODS: We conducted a case-series investigation, molecular typing of viral isolates, surveys of rates (...) of vaccination coverage, interviews regarding attitudes toward vaccination, and cost surveys. RESULTS: Approximately 500 persons attended a gathering with the index patient one day after her return home. Approximately 50 lacked evidence of measles immunity, of whom 16 (32 percent) acquired measles at the gathering. During the six weeks after the gathering, a total of 34 cases of measles were confirmed. Of the patients with confirmed measles, 94 percent were unvaccinated, 88 percent were less than 20 years

NEJM2006

64. Chinese medicinal herbs for measles.

Chinese medicinal herbs for measles. BACKGROUND: Measles is an infectious disease caused by Morbillivirus. Chinese physicians believe that medicinal herbs are effective in alleviating symptoms and preventing complications. Chinese herbal medicines are dispensed according to the particular symptoms. OBJECTIVES: To assess the effectiveness and possible adverse events of Chinese medicinal herbs in treating measles. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Clinical (...) Trials (CENTRAL) (The Cochrane Library Issue 4, 2005); MEDLINE (1966 to June 2005); EMBASE (1980 to June 2005); the Chinese Biomedical Database (1976 to June 2005); VIP Information (1989 to June 2005); China National Knowledge Infrastructure (CNKI) (1994 to June 2005); and the metaRegister of Controlled Trials was searched for ongoing trials. SELECTION CRITERIA: Randomised controlled trials (RCTs) in which patients with measles without complications were treated with Chinese medicinal herbs were

Cochrane2006

65. Measles, rubella, mumps, and varicella seroprevalence among health care workers in Turkey: is prevaccination screening cost-effective?

Measles, rubella, mumps, and varicella seroprevalence among health care workers in Turkey: is prevaccination screening cost-effective? Measles, rubella, mumps, and varicella seroprevalence among health care workers in Turkey: is prevaccination screening cost-effective? Measles, rubella, mumps, and varicella seroprevalence among health care workers in Turkey: is prevaccination screening cost-effective? Celikbas A, Ergonul O, Aksaray S, Tuygun N, Esener H, Tanir G, Eren S, Baykam N, Guvener E (...) , Dokuzoguz B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study investigated the use of a programme for screening health care workers for their immunity to measles, rubella, mumps and varicella (MMRV), with those with no immunity

NHS Economic Evaluation Database.2006

67. Prophylactic antibiotics to prevent pneumonia and other complications after measles: community based randomised double blind placebo controlled trial in Guinea-Bissau.

Prophylactic antibiotics to prevent pneumonia and other complications after measles: community based randomised double blind placebo controlled trial in Guinea-Bissau. 17060336 2006 12 15 2007 01 03 2016 12 15 1756-1833 333 7581 2006 Dec 16 BMJ (Clinical research ed.) BMJ Prophylactic antibiotics to prevent pneumonia and other complications after measles: community based randomised double blind placebo controlled trial in Guinea-Bissau. 1245 To investigate whether prophylactic antibiotics can (...) prevent complications of measles. Community based, randomised, double blind, placebo controlled trial. Bandim Health Project study area in Bissau, Guinea-Bissau, west Africa. 84 patients with measles during a measles epidemic in Bissau in 1998 (fewer than originally planned owing to interruption by war). Sulfamethoxazole-trimethoprim (co-trimoxazole) or placebo for seven days. Pneumonia and admission to hospital. Also weight change during the first month of infection, diarrhoea, severe fever, oral

BMJ2006 Full Text: Link to full Text with Trip Pro

68. Review: existing epidemiological evidence does not show an association between mumps, measles, and rubella vaccination and autism

Review: existing epidemiological evidence does not show an association between mumps, measles, and rubella vaccination and autism Review: existing epidemiological evidence does not show an association between mumps, measles, and rubella vaccination and autism | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: existing epidemiological evidence does not show an association between mumps, measles, and rubella vaccination and autism Article Text Causation Review: existing epidemiological evidence does

Evidence-Based Nursing (Requires free registration)2005

69. Measles, mumps, and rubella vaccine was not associated with autism in children

Measles, mumps, and rubella vaccine was not associated with autism in children Measles, mumps, and rubella vaccine was not associated with autism in children | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Measles, mumps, and rubella vaccine was not associated with autism in children Article Text Causation Measles, mumps, and rubella vaccine was not associated with autism in children Free Stephanie Wright , CFNP, CPNP, PhD Statistics from Altmetric.com No Altmetric data available for this article

Evidence-Based Nursing (Requires free registration)2004

70. Cost-effectiveness of three different vaccination strategies against measles in Zambian children

Cost-effectiveness of three different vaccination strategies against measles in Zambian children Cost-effectiveness of three different vaccination strategies against measles in Zambian children Cost-effectiveness of three different vaccination strategies against measles in Zambian children Dayan G H, Cairns L, Sangrujee N, Mtonga A, Nguyen V, Strebel P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three vaccination strategies against measles were examined. In the first (strategy 1), one dose of measles vaccine was delivered through the routine health care system at 9 months of age. In the second (strategy 2), one dose of measles vaccine was delivered through the routine health care system at 9 months of age

NHS Economic Evaluation Database.2004

71. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States

An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States Zhou F J, Reef S, Massoudi M, Papania M J, Yusuf H R, Bardenheier B, Zimmerman L, McCauley M M Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A two-dose measles-mumps-rubella (MMR) vaccination programme was compared with no vaccination and with a one-dose MMR vaccination scheme. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis and cost-benefit

NHS Economic Evaluation Database.2004

72. Measles: not just another viral exanthem.

Measles: not just another viral exanthem. Measles is the most frequent cause of vaccine-preventable childhood deaths. Infants younger than the recommended age for vaccination are susceptible to the disease, and in developing countries they have a high risk of complications and mortality. Vaccine coverage in excess of 95% interrupts endemic transmission of measles in many countries, but achievement of such coverage almost always requires coordinated supplementary mass vaccination campaigns (...) . There are substantial health gains if countries improve measles vaccine coverage, irrespective of whether or not high coverage is achieved; these gains include much lower measles complication and case fatality rates, long-term interepidemic duration, and possibly non-specific improvements in survival of children. Investigation into the cost-effectiveness of different strategies for measles control, including mass campaigns, two-dose schedules, and young-infant doses, would help countries to formulate control

Lancet2003

73. Association of autistic spectrum disorder and the measles, mumps, and rubella vaccine: a systematic review of current epidemiological evidence

Association of autistic spectrum disorder and the measles, mumps, and rubella vaccine: a systematic review of current epidemiological evidence Association of autistic spectrum disorder and the measles, mumps, and rubella vaccine: a systematic review of current epidemiological evidence Association of autistic spectrum disorder and the measles, mumps, and rubella vaccine: a systematic review of current epidemiological evidence Wilson K, Mills E, Ross C, McGowan J, Jadad A CRD summary This review (...) assessed the association between autistic spectrum disorder (ASD) and the measles, mumps and rubella (MMR) vaccine. The authors found no association between ASD and MMR, but there was insufficient evidence to completely exclude a possible association between MMR and a rare variant form of ASD. This was a well-conducted review, but the quality and nature of the included studies were varied. Authors' objectives To review evidence for and against the existence of an association between autistic spectrum

DARE.2003

74. The measles-mumps-rubella vaccine (MMR) and autism

The measles-mumps-rubella vaccine (MMR) and autism The measles-mumps-rubella vaccine (MMR) and autism The measles-mumps-rubella vaccine (MMR) and autism Higgins S Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Higgins S. The measles-mumps-rubella vaccine (MMR) and autism. Clayton, Victoria: Centre for Clinical Effectiveness (CCE) 2003: 14 Authors' objectives (...) This aim of this critical appraisal was to assess whether the combined measles-mumps-rubella vaccine (MMR) given according to the Department of Health's immunisation schedule increase the child's risk of developing autism. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Autistic Disorder; Measles-Mumps-Rubella Vaccine /adverse effects Language Published English Country of organisation Australia Address for correspondence Monash Institute of Health Services Research, Block E

Health Technology Assessment (HTA) Database.2003

75. Differences in female-male mortality after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus-pertussis and inactivated poliovirus: reanalysis of West African studies.

Differences in female-male mortality after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus-pertussis and inactivated poliovirus: reanalysis of West African studies. 12842371 2003 07 04 2003 07 17 2015 06 16 1474-547X 361 9376 2003 Jun 28 Lancet (London, England) Lancet Differences in female-male mortality after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus-pertussis and inactivated poliovirus (...) : reanalysis of West African studies. 2183-8 Females given high-titre measles vaccine (HTMV) have high mortality; diphtheria-tetanus-pertussis (DTP) vaccination might be associated with increased female mortality. We aimed to assess whether DTP or inactivated poliovirus (IPV) administered after HTMV was associated with increased female-male mortality ratio. In three trials from West Africa, 2000 children were randomised to HTMV or control vaccine at 4-5 months of age; a second vaccination was given at age

Lancet2003

76. A population-based study of measles, mumps, and rubella vaccination and autism.

A population-based study of measles, mumps, and rubella vaccination and autism. BACKGROUND: It has been suggested that vaccination against measles, mumps, and rubella (MMR) is a cause of autism. METHODS: We conducted a retrospective cohort study of all children born in Denmark from January 1991 through December 1998. The cohort was selected on the basis of data from the Danish Civil Registration System, which assigns a unique identification number to every live-born infant and new resident (...) in Denmark. MMR-vaccination status was obtained from the Danish National Board of Health. Information on the children's autism status was obtained from the Danish Psychiatric Central Register, which contains information on all diagnoses received by patients in psychiatric hospitals and outpatient clinics in Denmark. We obtained information on potential confounders from the Danish Medical Birth Registry, the National Hospital Registry, and Statistics Denmark. RESULTS: Of the 537,303 children in the cohort

NEJM2002

77. First 5 years of measles elimination in southern Africa: 1996-2000.

First 5 years of measles elimination in southern Africa: 1996-2000. BACKGROUND: Measles is the leading cause of vaccine-preventable death in Africa. Regional measles elimination is considered feasible using current vaccines and a series of WHO-recommended strategies. We aimed to interrupt transmission of measles, and to use case-based surveillance to show the effect of such interruption. METHODS: In southern Africa from 1996, seven countries with a total population of approximately 70 million (...) and with relatively high routine vaccination coverage implemented measles elimination strategies. In addition to routine measles immunisation at 9 months of age, these included nationwide catch-up campaigns among children aged 9 months to 14 years, then follow-up campaigns every 3-4 years among children aged 9-59 months, and the establishment of case-based measles surveillance with serological diagnostic confirmation. RESULTS: Nearly 24 million children aged 9 months to 14 years were vaccinated, with overall

Lancet2002

78. Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study.

Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. OBJECTIVES: To investigate whether measles, mumps, and rubella (MMR) vaccination is associated with bowel problems and developmental regression in children with autism, looking for evidence of a "new variant" form of autism. DESIGN: Population study with case note review linked to independently recorded vaccine data. SETTING: Five health districts in north east (...) London. PARTICIPANTS: 278 children with core autism and 195 with atypical autism, mainly identified from computerised disability registers and born between 1979 and 1998. MAIN OUTCOME MEASURES: Recorded bowel problems lasting at least three months, age of reported regression of the child's development where it was a feature, and relation of these to MMR vaccination. RESULTS: The proportion of children with developmental regression (25% overall) or bowel symptoms (17%) did not change significantly (P

BMJ2002 Full Text: Link to full Text with Trip Pro

79. Effect of vitamin A supplementation on measles-specific antibody levels in Guinea-Bissau.

Effect of vitamin A supplementation on measles-specific antibody levels in Guinea-Bissau. 11965280 2002 04 19 2002 04 30 2015 06 16 0140-6736 359 9314 2002 Apr 13 Lancet (London, England) Lancet Effect of vitamin A supplementation on measles-specific antibody levels in Guinea-Bissau. 1313-4 We have previously reported that vitamin A supplementation with measles vaccine at age 9 months increases measles-specific antibody concentrations in children at age 18 months compared with placebo. We (...) examined these children when they reached age 6-8 years. Fewer vitamin A-supplemented children had non-protective antibody concentrations (p=0.0095); among children with protective antibody levels, vitamin A-supplemented children tended to have higher geometric mean antibody titres (p=0.09). Thus, simultaneous administration of vitamin A and measles vaccine at age 9 months had a long-term effect on measles-specific antibody levels and may contribute to improved measles control in less-developed

Lancet2002

80. Vitamin A for treating measles in children.

Vitamin A for treating measles in children. BACKGROUND: Measles is a leading cause of childhood morbidity and mortality. Vitamin A deficiency is a recognised risk factor for severe measles. The World Health Organization (WHO) recommends administration of an oral dose of 200,000 IU (or 100,000 IU in infants) of vitamin A per day for two days to children with measles in areas where vitamin A deficiency may be present. OBJECTIVES: The purpose of this review is to determine whether vitamin A when (...) commenced after measles has been diagnosed, is beneficial in preventing mortality, pneumonia and other complications in children. SEARCH STRATEGY: MEDLINE and the Cochrane Library, Issue 4, 1999 were searched. SELECTION CRITERIA: Only randomized controlled trials in which children with measles were given vitamin A or placebo along with standard treatment were considered. DATA COLLECTION AND ANALYSIS: Studies were assessed independently by two reviewers. The analysis of dichotomous outcomes was done

Cochrane2002